Clinical trials in metastatic prostate cancer - Has there been real progress in the past decade?

European Journal of Cancer

Volumn 41, Issue 6, 2005, Pages 941-953

  Bhandari, Manish S ^a   Petrylak, Daniel P ^b   Hussain, Maha ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Chemotherapy; Clinical trials; Docetaxel; Epothilone; Hormone refractory; Prostate cancer; Targeted therapies

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ATRASENTAN; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CILENGITIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ENDOTHELIN RECEPTOR ANTAGONIST; EPIRUBICIN; EPOTHILONE DERIVATIVE; ESTRAMUSTINE; ETOPOSIDE; HYDROCORTISONE; IXABEPILONE; KETOCONAZOLE; LENALIDOMIDE; MITOXANTRONE; NAVELBINE; OBLIMERSEN; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEASOME; RISEDRONIC ACID; STRONTIUM 82; SURAMIN; TAXANE DERIVATIVE; UNINDEXED DRUG; VINBLASTINE;

ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLOOD CLOTTING DISORDER; BREAST DISEASE; BREAST TENDERNESS; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; DROWSINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HORMONAL THERAPY; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; KIDNEY FAILURE; LETHARGY; LIBIDO DISORDER; METASTASIS; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; RASH; REVIEW; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM;

EID: 16244378263     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.02.008     Document Type: Article

References (116)

1. A. Jemal, T. Murray, and E. Ward Cancer statistics, 2005 CA Cancer J Clin 55 2005 10 30
2. M. Han, A.W. Partin, and C.R. Pound Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience Urol Clin North Am 28 2001 555
3. J.J. Coen, A.L. Zietman, and H. Thakral Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases J Clin Oncol 20 2002 3199
4. P.R. Carroll, P. Kantoff, and W. Balk Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer Urology 60 Suppl. 2002 1
5. G.W. Chodak, T. Keane, and L. Klotz Critical evaluation of hormonal therapy for carcinoma of the prostate Urology 60 2002 201
6. Wm. Kelly, and H.I. Scher Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome J Urol 149 1993 607
7. E.J. Small, S. Halabi, and J. Picus A prospective randomized trial of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in androgen independent prostate cancer patients: results of CALGB 9583 Proc Am Soc Clin Oncol 20 2001 174a
8. K.A. Harris, V. Weinberg, and R.A. Bok Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer J Urol 168 2002 542
9. E.J. Small, and N.J. Vogelzang Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm J Clin Oncol 15 1997 382
10. R.S. DiPaola, J. Patel, and M.M. Rafi Targeting apoptosis in prostate cancer Hematol Oncol Clin North Am 15 2001 509
11. S. Culine, and J.P. Droz Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress Ann Oncol 11 2000 1523
12. R. Benson, and B. Hartley-Asp Mechanisms of action and clnical uses of estramustine Cancer Invest 8 1990 375
13. A. Yagoda, and D. Petrylak Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer Cancer 71 1993 1098 1109
14. A. Yagoda, D. Petrylak, and S. Thompson Cytotoxic chemotherapy for advanced renal cell carcinoma Urol Clin North Amer 20 1993 303 321
15. I.F. Tannock, D. Osaba, and M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756
16. D. Osaba, I.F. Tannock, and D.S. Ernst Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone J Clin Oncol 17 1999 1654
17. P.W. Kantoff, S. Halabi, and M. Conaway Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study J Clin Oncol 17 1999 2506
18. J. Picus, and M. Schultz Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results Semin Oncol 26 1999 14
19. D. Friedland, J. Cohen, and R. Miller Jr. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2 Semin Oncol 26 1999 19
20. T.M. Beer, W.C. Pierce, and B.A. Lowe Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer Ann Oncol 12 2001 1273 1279
21. W. Berry, S. Dakhil, and M.A. Gregurich Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate Semin Oncol 28 2001 8 15
22. B.J. Roth, B.Y. Yeap, and G. Wilding Taxol in advanced, hormone-refractory carcinoma of the prostate: a phase II trial of the Eastern Cooperative Oncology Group Cancer 72 1993 2457 2460
23. C. Trivedi, B. Redman, and L.E. Flaherty Weekly 1-hour infusion of paclitaxel: clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma Cancer 89 2000 431 436
24. W. Berry, M. Gregurich, and S. Dakhil Phase II randomized trial of weekly paclitaxel (Taxol) with or without estramustine phosphate in patients with symptomatic, hormone-refractory, metastatic carcinoma of the prostate (HRMCP) Proc Am Soc Clin Oncol 20 2001 175a (abstract 696)
25. W. Berry, S. Dakhil, and M. Modiano Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer J Urol 168 2002 2439 2443
26. D. Raghavan, K. Cox, and B.S. Pearson Oral cyclophosphamide for the management of hormone-refractory prostate cancer Br J Urol 72 1993 625 628
27. R. Nogueira-Costa, L. Ramos, and R. Duarte Oral cyclophosphamide (CTX) for chemotherapy-naive (CT-N) hormone-refractory prostate cancer (HRPC) Proc Am Soc Clin Oncol 18 1999 349a (abstract 1345)
28. A. Yagoda, J.A. Smith, and M.S. Soloway Phase II study of estramustine phosphate in advanced hormone refractory prostate cancer with increasing prostate specific antigen levels J Urol 145 1991 384A (abstract 686)
29. S. Fields-Jones, A. Koletsky, and G. Wilding Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial Ann Oncol 10 1999 1307 1310
30. R. Morant, S.F. Hsu Schmitz, and J. Bernhard Vinorelbine in androgen-independent metastatic prostatic carcinoma: a phase II study Eur J Cancer 38 2002 1626 1632
31. S. Oudard, A. Caty, and Y. Humblet Phase II study of vinorelbine in patients with androgen-independent prostate cancer Ann Oncol 12 2001 847 852
32. C. Rangel, H. Matzkin, and M.S. Soloway Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer Urology 39 1992 577 582
33. G. Francini, R. Petrioli, and A. Manganelli Weekly chemotherapy in advanced prostatic cancer Br J Cancer 67 1993 1430 1436
34. M. Brausi, W.G. Jones, and S.D. Fossa High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group Eur J Cancer 31A 1995 1622 1626
35. K.P. Delaere, H. Leliefeld, and F. Peulen Phase II study of epirubicin in advanced hormone-resistant prostatic carcinoma Br J Urol 70 1992 641 642
36. R. Petrioli, A.I. Fiaschi, and D. Pozzessere Weekly epirubicin in patients with hormone-resistant prostate cancer Br J Cancer 87 2002 720 725
37. M.E. Stearns, and K.D. Tew Antimicrotubule effects of estramustine, an antiprostatic tumor drug Cancer Res 45 1985 3891 3897
38. M.E. Stearns, M. Wang, and K.T. Tew Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization of DU-145 cells J Cell Biol 107 1988 2647 2656
39. B. Dahllof, A. Billstrom, and F. Cabral Estramustine depolymerizes microtubules by binding to tubulin Cancer Res 53 1993 4573 4581
40. K.J. Pienta, and J.E. Lehr Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix J Urol 149 1993 1622 1625
41. L.A. Speicher, L. Barone, and K.D. Tew Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines Cancer Res 52 1992 4433 4440
42. T. Kitamura Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer Int J Urol 8 2 2001 33 36
43. D.M. Savarese, S. Halabi, and V. Hars Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B J Clin Oncol 19 2001 2509 2516
44. M.S. Copur, P. Ledakis, and J. Lynch Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer Semin Oncol 28 2001 16 21
45. V.J. Sinibaldi, M.A. Carducci, and S. Moore-Cooper Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma Cancer 94 2002 1457 1465
46. G.R. Hudes, F. Nathan, and C. Khater Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer J Clin Oncol 15 1997 3156 3163
47. A.C. Ferrari, A. Chachoua, and H. Singh A phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma Cancer 91 2001 2039 2045
48. U. Vaishampayan, J. Fontana, and W. Du An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer Urology 60 2002 1050 1054
49. A. Athanasiadis, D. Tsavdaridis, and S.K. Rigatos Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination Anticancer Res 23 2003 3085 3088
50. K.J. Pienta, B. Redman, and M. Hussain Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate J Clin Oncol 12 1994 2005 2012
51. K.J. Pienta, B.G. Redman, and R. Bandekar A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer Urology 50 1997 401 406 (discussion 406-407)
52. M.A. Dimopoulos, C. Panopoulos, and C. Bamia Oral estramustine and oral etoposide for hormone-refractory prostate cancer Urology 50 1997 754 758
53. K.J. Pienta, E.I. Fisher, and M.A. Eisenberger A phase II trial of estramustine and etoposide in hormone refractory prostate cancer A Southwest Oncology Group trial (SWOG 9407) Prostate 46 2001 257 261
54. D.C. Smith, P. Esper, and M. Strawderman Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer J Clin Oncol 17 1999 1664 1671
55. R. Millikan, P.F. Thall, and S.J. Lee Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer J Clin Oncol 21 2003 878 883
56. W.K. Kelly, T. Curley, and S. Slovin Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer J Clin Oncol 19 2001 44 53
57. S. Urakami, M. Igawa, and N. Kikuno Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer J Urol 168 2002 2444 2450
58. J.A. Ellerhorst, S.M. Tu, and R.J. Amato Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer Clin Cancer Res 3 1997 2371 2376
59. G. Hudes, L. Einhorn, and E. Ross Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial J Clin Oncol 17 1999 3160 3166
60. M.R. Smith, D. Kaufman, and W. Oh Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study Cancer 89 2000 1824 1828
61. J. Carles, M. Domenech, and A. Gelabert-Mas Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients Acta Oncol 37 1998 187 191
62. C.J. Sweeney, F.J. Monaco, and S.H. Jung A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer Ann Oncol 13 2002 435 440
63. J.P. Armand, and E. Cvitkovic Suramin: a new therapeutic concept Eur J Cancer 26 1990 417 419
64. M.M. Walther, W.D. Figg, and W.M. Lineham Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder World J Urol 14 suppl. 1 1996 S8 S11
65. M.A. Eisenberger, V. Sinibaldi, and R.L. Suramin Cancer Pract 3 1995 187 189
66. J.P. Armand NEW anticancer drugs in Europe Chin Med J 110 1997 297 308
67. M.A. Eisenberger, and J.A. Fontana Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer: compelling reasons for testing in patients with hormone refractory breast cancer J Natl Cancer Inst 84 1992 3 5
68. C. Myers, M. Cooper, and C. Stein Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer J Clin Oncol 10 1992 881 889
69. C.A. Stein, R. LaRocca, and R. Thomas Suramin - an anticancer drug with a unique mechanism of action J Clin Oncol 7 1989 449 508
70. C. Myers, R. LaRocca, and M. Cooper Role of suramin in cancer biology and treatment 1991 Williams and Wilkins Baltimore
71. K. Kobayshi, E.E. Vokes, and N.J. Vogelzang Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer J Clin Oncol 13 1995 2196 2207
72. M.A. Eisenberger, V.J. Sinibaldi, and L.M. Reyno Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer J Clin Oncol 13 1995 2174 2186
73. N.A. Dawson, M.R. Cooper, and W.D. Figg Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables Cancer 76 1995 453 462
74. E.J. Small, M. Meyer, and M.E. Marshall Suramin therapy for patients with symptomatic hormone refractory prostate cancer; results of a phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortsone J Clin Oncol 18 7 2000 1440 1450
75. M. Hussain, E.I. Fisher, and D.P. Petrylak Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: a southwest oncology group study J Clin Oncol 18 2000 1043 1049
76. D.P. Petrylak, C. Tangen, and M. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 15 2004 1513 1520
77. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 15 2004 1502 1512
78. G. Hudes Signaling receptors in the treatment of prostate cancer Invest New Drugs 20 2 2002 159 172
79. A.K. David, R. Khwaja, and G.R. Hudes Treatments for improving survival of patients with prostate cancer Drugs Aging 20 9 2003 683 699
80. M. Hussain, J. Faulkner, and U. Vaishampayan Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (S0111) Proc Am Soc Clin Oncol 23 2004 383 (abstract 4510)
81. W.K. Kelly, M.D. Galsky, and E.J. Small Multi-institutional trial of the epothilone B analogue BMS-247550 with or without estramustine phosphate (EMP) in patients with progressive castrate-metastatic prostate cancer (PCMPC): updated results Proc Am Soc Clin Oncol 23 2004 383 (abstract 4509)
82. J.E. Rosenberg, M.D. Galsky, and V. Weinberg Response to second-line taxane-based therapy after first-line epothilone B analogue BMS-247550 (BMS) therapy in hormone refractory prostate cancer (HRPC) Proc Am Soc Clin Oncol 23 2004 396 (abstract 4564)
83. R. Dreicer, B. Roth, and D.P. Petrylak Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer Proc Am Soc Clin Oncol 23 2004 418 (abstract 4654)
84. W.D. Figg, W. Dahut, and P. Duray A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer Clin Cancer Res 7 2001 1888 1893
85. W.L. Dahut, J.L. Gulley, and P.M. Arlen Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer J Clin Oncol 22 13 2004 2532 2539
86. J. Picus, S. Halabi, and B.I. Rini The use of bevacizumab Proc Am Soc Clin Oncol 22 2004 1578A
87. 3 integrin antagonists J Med Chem 42 1999 3033 3040
88. P.C. Brooks Role of integrins in angiogenesis Eur J Cancer 32 1996 A2423 A2429
89. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Cell 79 1994 1157 1164
90. J.B. Nelson Endothelin inhibition: novel therapy for prostate cancer J Urol 170 2003 S65 S67
91. M.A. Carducci, R.J. Padley, and J. Breul Effect of endothelin - a receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trail J Clin Oncol 21 4 2003 679 689
92. M.A. Carducci, J.B. Nelson, and F. Saad Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study Proc Am Soc Clin Oncol 22 2004 41S (abstract 4508)
93. T.J. McDonnell, P. Troncoso, and S.M. Brisbay Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer Cancer Res 52 1992 6940 6944
94. A.J. Raffo, H. Perlman, and M.W. Chen Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo Cancer Res 55 1995 4438 4445
95. M. Gleave, A. Tolcher, and H. Miyake Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model Clin Cancer Res 5 1999 2891 2898
96. M. Colombel, F. Symmans, and S. Gil Detection of the apoptosis- suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers Am J Pathol 143 1993 390 400
97. I. Apakama, M.C. Robinson, and N.M. Walter bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer Br J Cancer 74 1996 1258 1262
98. T.J. McDonnell, N.M. Navone, and P. Troncoso Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer J Urol 157 1997 569 574
99. A. Tolcher, M. Gleave, and B. Brown Antisense bcl-2 oligonucleotides inhibit the progression to androgen-independence (AI) after castration in the LNCaP tumor model Proc Am Assoc Cancer Res 39 1998 417
100. A.W. Tolcher, S. Roth, and S. Wynne G3139 (Genasense) enhances docetaxel antitumor activity and leads to long-term survivors in the androgen-independent prostate cancer xenograph (PC3) model Clin Cancer Res 7 2001 3680s
101. A.W. Tolcher, J. Kuhn, and G. Schwartz A phase I pharmacokinetic and biological correlative study of oblimersen sodium (Genasense, G3139), an antisense oligonucleotide to the Bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer Clin Cancer Res 10 2004 5048 5057
102. I.F. Tannock Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate J Clin Oncol 3 1985 1013 1021
103. W.K. Oh, P. Tully, and P.W. Kantoff Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma Cancer 97 2003 2171
104. P. Sabbatini, S.M. Larson, and A. Kremer Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer J Clin Oncol 17 1999 948 957
105. P.H. Smith, A. Bono, and F. Calais da Silva Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer - a sub-analysis of EORTC trial 30853. The EORTC Urological Group Cancer 66 1990 1009 1016
106. R.L. Prentice Surrogate endpoints in clinical trials: definition and operational criteria Stat Med 8 4 1989 431 440
107. H.I. Scher, W.M. Kelly, and Z.F. Zhang Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer J Natl Cancer Inst 91 1999 244 251
108. R. Sridhara, M.A. Eisenberger, and V.J. Sinibaldi Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy J Clin Oncol 13 1995 2944 2953
109. M.A. Eisenberger, B.A. Blumenstein, and E.D. Crawford Bilateral orchiectomy with or without flutamide for metastatic prostate cancer N Engl J Med 339 1998 1036 1042
110. G.J. Bubley, M. Carducci, and W. Dahut Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 11 1999 3461 3467
111. E.D. Crawford, D.K. Pauler, and C.M. Tangen Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916 Proc Am Soc Clin Oncol 23 2004 382 (abstract 4505)
112. G.J. Kelloff, C.C. Sigman, and K.M. Johnson Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer Cancer Epidemiol Biomarkers Prev 9 2000 127 137
113. Skinner EC, Glode LM. High-risk localized prostate cancer: primary surgery and adjuvant therapy. Urol Oncol: Semin Orig Invest 21, 219-227
114. Simon et al. Cancer Treat Rep 2003, 69, 1375-1381
115. J.E. Husband, L.H. Schwartz, and J. Spencer Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society Br J Cancer 12 2004 2256 2260
116. W. Stadler New trial designs to assess antitumor and antiproliferative agents in prostate cancer Invest New Drugs 20 2002 201 208